Skip to content

Electrophysiological Characteristics of Bayés Syndrome: Predictive Value for Atrial Fibrillation Ablation Outcomes and Stroke

Electrophysiological Characteristics of Bayés Syndrome: Predictive Value for Atrial Fibrillation Ablation Outcomes and Stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126477
Enrollment
Unknown
Registered
2026-06-09
Start date
2026-06-20
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation Interatrial block Bayés syndrome

Interventions

Study Group:None
Control Group:None

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Study Group: 1. Age = 18 years, no restriction on gender; 2. Successfully completed atrial fibrillation catheter ablation; 3. At screening, a 12-lead ECG showing sinus rhythm meeting the diagnostic criteria for interatrial conduction block, excluding P wave widening caused by other reasons. Control Group: 1. Age = 18 years, no restriction on gender; 2. Successfully completed atrial fibrillation catheter ablation; 3. At screening, ECG confirmed sinus rhythm (heart rate 60-100 beats per minute).

Exclusion criteria

Exclusion criteria: Exclusion criteria for the study group: 1. Valvular AF, such as after mechanical valve replacement or moderate to severe rheumatic mitral stenosis; 2. Combined with other known diseases that can cause cardiovascular adverse events (such as hyperthyroidism, history of cardiac surgery, etc.); 3. History of radiofrequency catheter ablation for all types of atrial arrhythmias and left atrial appendage closure surgery; 4. Patients with cardiac pacemaker implantation; 5. Presence of other causes leading to P wave widening: (1) Significant enlargement of the left atrium/right atrium (echocardiographic left atrial anterior-posterior diameter >= 50 mm or right atrial transverse diameter >= 45 mm); (2) Electrolyte disorders (serum potassium 5.5 mmol/L); (3) Uncontrolled hyperthyroidism or hypothyroidism; (4) Taking drugs affecting atrial conduction (such as amiodarone, propafenone, sotalol, etc., with a discontinuation time of < 5 half-lives). Exclusion criteria for the control group: 1. Valvular AF, such as after mechanical valve replacement or moderate to severe rheumatic mitral stenosis; 2. Combined with other known diseases that can cause cardiovascular adverse events (such as hyperthyroidism, history of cardiac surgery, etc.); 3. History of radiofrequency catheter ablation for all types of atrial arrhythmias and left atrial appendage closure surgery; 4. Patients with cardiac pacemaker implantation.

Design outcomes

Primary

MeasureTime frame
>30s ventricular arrhythmia occurs;Death due to cardiovascular events;Relapse;

Countries

China

Contacts

Public ContactXiaomeng Yin

The First Affiliated Hospital of Dalian Medical University

dr.yinxm@163.com+86 411 8363 5963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026